

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

REGENERON PHARMACEUTICALS, INC.,
Petitioner,

v.

NOVARTIS PHARMA AG,
NOVARTIS TECHNOLOGY LLC,
NOVARTIS PHARMACEUTICALS CORPORATION,
Patent Owner.

PETITION FOR INTER PARTES REVIEW

OF

U.S. PATENT NO. 9,220,631

TABLE OF CONTENTS

I.	INTRODUCTION	1
II.	MANDATORY NOTICES	1
	A. Real Party-in-Interest	1
	B. Related Matters.....	1
	C. Lead and Back-up Counsel and Service Information	3
III.	GROUNDS FOR STANDING.....	3
IV.	35 U.S.C. §§ 314(a), 325(d)	3
V.	TECHNOLOGY BACKGROUND.....	11
	A. Pre-filled Syringes for Intravitreal Injection	11
	B. Syringe Barrel Siliconization	12
	C. Sterilization of Pre-Filled Syringes	15
	D. Particulate Content	16
VI.	THE '631 PATENT	17
	A. The Challenged Claims	17
	B. The Specification.....	18
	1. Siliconization Methods and Alleged Surprising Results	18
	2. Terminal Sterilization	18
	3. Particulate Content.....	19
	C. The Prosecution History	19
VII.	STATUTORY GROUNDS FOR THE CHALLENGES	21
VIII.	LEVEL OF ORDINARY SKILL IN THE ART	24
IX.	CLAIM CONSTRUCTION	24
	A. “Stopper Break Loose Force”	24
	B. “Stopper Slide Force”	25
	C. “Terminally sterilized”	25
	D. “About”.....	25

X.	IDENTIFICATION OF HOW THE CHALLENGED CLAIMS ARE UNPATENTABLE.....	26
A.	Ground 1: Sigg in view of Boulange.....	26
	1. Overview of Sigg	26
	2. Overview of Boulange	27
	3. Motivation to Combine and Reasonable Expectation of Success	31
	4. Claim 1	40
	5. Claims 2, 3, 5-9, 14, 16-22 and 24.....	47
	6. Claim 15.....	54
B.	Ground 2: Lam in view of Boulange.....	55
	1. Overview of Lam	56
	2. Claim 1	56
	3. Claims 2, 3, 5-9, 14-22, and 24.....	59
C.	Grounds 3 and 4: Sigg or Lam in view of Boulange and Fries.....	65
D.	Grounds 5 and 6: Sigg or Lam in view of Boulange and Furfine.....	67
E.	Grounds 7 and 8: Sigg or Lam in view of Boulange and 2008 Macugen Label	68
F.	Grounds 9 and 10: Sigg or Lam in view of Boulange and Dixon	70
XI.	SECONDARY CONSIDERATIONS	71
XII.	CONCLUSION.....	74

PETITIONER'S EXHIBIT LIST

Ex. 1001	U.S. Patent No. 9,220,631 (“the ’631 Patent”)
Ex. 1002	Prosecution File History of U.S. Patent No. 9,220,631
Ex. 1003	Declaration of Horst Koller under 37 C.F.R. § 1.68.
Ex. 1004	Curriculum Vitae of Horst Koller
Ex. 1005	ITC Investigation No. 337-TA-1207, Staff’s Pre-Hearing Brief (public version)
Ex. 1006	ITC Investigation No. 337-TA-1207, Complainant’s Unopposed Motion to Terminate
Ex. 1007	PCT Patent Publication No. WO 2011/006877 to Sigg <i>et al.</i> (“Sigg”)
Ex. 1008	PCT Patent Publication No. WO 2009/030976 to Boulange <i>et al.</i> (“Boulange”)
Ex. 1009	Internet Archive WayBack Machine, March 7, 2011 Record of Drugs.com, <i>Macugen Prescribing Information</i> , available at https://web.archive.org/web/20110307065238/http://www.drugs.com:80/pro/macugen.html (“2008 Macugen Label”)
Ex. 1010	ITC Investigation No. 337-TA-1207, Initial Determination Terminating the Investigation
Ex. 1011	Bhavnes D. Shah & Bhupendra G. Prajapati, <i>Pre-Filled Syringes: A New Concept</i> , PHARMA BIO WORLD 51 (2009) (“Shah”)
Ex. 1012	Arno Fries, <i>Drug Delivery of Sensitive Biopharmaceuticals With Prefilled Syringes</i> , 9(5) DRUG DELIVERY TECH. 22 (2009) (“Fries”)

Ex. 1013	Thomas Schoenknecht, <i>Prefilled Syringes: Why New Developments Are Important In Injectable Delivery Today</i> , in PREFILLED SYRINGES INNOVATIONS THAT MEET THE GROWING DEMAND (OnDrugDelivery 2005) (“Schoenknecht”)
Ex. 1014	U.S. Patent Publication No. 2012/0091026 to Chacornac <i>et al.</i> (“Chacornac”)
Ex. 1015	Sandeep Nema & John D. Ludwig, <i>Pharmaceutical Dosage Forms: Parenteral Medications, Volume 1: Formulation and Packaging</i> (3rd ed. 2010) (“Nema Vol. 1”)
Ex. 1016	Sandeep Nema & John D. Ludwig, <i>Pharmaceutical Dosage Forms: Parenteral Medications, Volume 2: Facility Design, Sterilization and Processing</i> (3rd ed. 2010) (“Nema Vol. 2”)
Ex. 1017	PCT Patent Publication No. WO 2007/035621 to Scypinski <i>et al.</i> (“Scypinski”)
Ex. 1018	U.S. Patent Publication No. 2003/0003014 to Metzner <i>et al.</i> (“Metzner”)
Ex. 1019	U.S. Pharmacopeia, <i>USP 789, Particulate Matter in Ophthalmic Solutions, USP 34 NF 29</i> (2011)
Ex. 1020	U.S. Patent Publication No. 2011/276005 to Hioki <i>et al.</i> (“Hioki”)
Ex. 1021	PCT Patent Publication No. WO 2007/149334 to Furfine <i>et al.</i> (“Furfine”)
Ex. 1022	Michael W. Stewart <i>et al.</i> , <i>Fresh From the Pipeline Aflibercept</i> , 11 NAT. REV. DRUG DISCOV. 269 (2012) (“Stewart”)
Ex. 1023	U.S. Patent No. 7,060,269 to Baca <i>et al.</i> (“Baca”)
Ex. 1024	Gerald McDonnel and Denver Russell, <i>Antiseptics and Disinfectants: Activities, Action, and Resistance</i> , Clinical Microbiology Review, (Jan. 1999) (“McDonnel”).

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.